Former Sandoz Inc. CEO Don DeGolyer Leads PharmaTech Startup Ategenos as Company Prepares Public Launch
CAMBRIDGE, Mass., July 22, 2025 /PRNewswire/ -- Ategenos, a pharmatech company, today announced that Co-Founder and Chief Executive Officer Don DeGolyer is leading the company as it prepares to exit stealth and unveil its platform addressing one of healthcare's most costly and persistent challenges: medication non-adherence.
Ategenos has been quietly developing a novel platform that integrates pharmaceutical science with real-time digital health technologies to address adherence in critical dose management. The company will share details on its SmartPatch platform and initial partnerships in the coming weeks.
'Medication doesn't work if it's not taken. Yet non-adherence remains one of the biggest drivers of avoidable healthcare costs worldwide,' said DeGolyer. 'From the start, we set out to build a platform that combines drug delivery, actionable real-world data, and caregiver intervention. We provide caregivers the peace of mind that their loved ones have taken their critical dose medicines and are not at risk of a catastrophic health event.'
Medication non-adherence contributes to an estimated 125,000 preventable deaths and more than $500 billion in avoidable healthcare costs annually in the U.S., with global costs exceeding $1 trillion each year.
DeGolyer brings over 40 years of leadership across the pharmaceutical industry. As President & CEO of Sandoz Inc., he grew revenues by $2 billion in four years, building one of the largest generics businesses in North America. As COO of Endo Pharmaceuticals, he helped scale the company from $2 billion to $18 billion in market cap within two years. He also founded and led Vertice Pharmaceuticals, doubling revenue during his tenure and building a platform that later contributed to a $700 million strategic sale. Don has held senior roles at Pfizer, Johnson & Johnson, and Novartis, advisory positions with Koch Investment Group and Formation Bio, and serves on the board of Emergent BioSolutions.
DeGolyer has built a founding team combining pharma leadership, MIT-rooted technology innovation, and venture capital expertise. With experience spanning drug delivery, IoT, real-world data, and company building, Ategenos is uniquely positioned to operate at the intersection of pharmaceuticals and technology.
About Ategenos
Ategenos is a Massachusetts-based PharmaTech company improving quality of life for patients and their families with its SmartPatch platform—an advanced transdermal system that combines sustained drug delivery with real-time monitoring and caregiver interventions. The technology reduces health risks, hospitalizations, and the $1T+ global costs caused by missed doses of critical medications. The company's founders uniquely combine global pharma leadership, MIT-driven technology, and a proven track record of building and scaling healthcare platforms.
For Media Inquiries: [email protected]
For Strategic Partnerships: [email protected]
For Investment Opportunities: [email protected]
View original content to download multimedia: https://www.prnewswire.com/news-releases/former-sandoz-inc-ceo-don-degolyer-leads-pharmatech-startup-ategenos-as-company-prepares-public-launch-302511102.html
SOURCE Ategenos Pharmaceuticals Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
CareTrust REIT (CTRE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
For the quarter ended June 2025, CareTrust REIT (CTRE) reported revenue of $112.47 million, up 63.3% over the same period last year. EPS came in at $0.43, compared to $0.07 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $107.52 million, representing a surprise of +4.6%. The company delivered an EPS surprise of -4.44%, with the consensus EPS estimate being $0.45. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately. Here is how CareTrust REIT performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- Rental income: $86.03 million versus $75.75 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +55.3% change. Revenues- Interest income from other real estate related investments and other income: $23.55 million versus $25.05 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +74.7% change. Net Earnings Per Share (Diluted): $0.35 compared to the $0.36 average estimate based on two analysts. View all Key Company Metrics for CareTrust REIT here>>> Shares of CareTrust REIT have returned +6% over the past month versus the Zacks S&P 500 composite's +0.5% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CareTrust REIT, Inc. (CTRE) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
23 minutes ago
- Yahoo
eBay Inc. (EBAY)'s Algorithims Are Working, Says Jim Cramer
We recently published . eBay Inc. (NASDAQ:EBAY) is one of the stocks Jim Cramer recently discussed. eBay Inc. (NASDAQ:EBAY) is an eCommerce retailer whose shares have gained 47% year-to-date. Most of these gains are due to an 18.3% jump in July after the firm's second-quarter earnings report. The results saw eBay Inc. (NASDAQ:EBAY) beat analyst second-quarter revenue and EPS estimates of $2.64 billion and $1.30 by posting $2.73 billion and $1.30, respectively. The firm's third quarter revenue guidance of $2.69 billion and $2.74 billion also overshot analyst estimates of $2.66 billion. Here's what Cramer believes about eBay Inc. (NASDAQ:EBAY)'s strong performance: 'Now one David, that I know that you will remember from the old days that really is putting on a good show, would be eBay. They've got their mojo back. It's up 15%, they had very good numbers, and I salute them. They hung in and now their model is working. They've got the algos working so to speak. And a lot of people upgraded it. That's to me, better focus, better focus.' Copyright: rawpixel / 123RF Stock Photo Earlier, Cramer discussed eBay Inc. (NASDAQ:EBAY)'s marketplace and shifting sentiment: 'There's no real theme to the other stocks on the list… eBay's a real shocker. It's come a long way to get back on this list. Now, I've watched this stock get carved up for ages, but now it looks like eBay has stopped being a whipping boy, and people are feeling comfortable buying merchandise second-hand. Has a partnership with Facebook's Marketplace, which has spurred real growth for the company. I like that, by the way, that marketplace section.' While we acknowledge the potential of EBAY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
23 minutes ago
- Yahoo
Study attributes 440 'excess deaths' to January's Los Angeles wildfires
By Steve Gorman LOS ANGELES (Reuters) -Wildfires that devastated parts of the Los Angeles area in January indirectly led to hundreds of deaths in the ensuing weeks, far exceeding the official toll of 31 fatalities, according to a study released on Wednesday. The research, published in the Journal of the American Medical Association, or JAMA, estimated 440 "excess deaths" were attributable to the fires from January 5 to February 1, using models that compared predicted mortality under normal circumstances to actual numbers documented during that period. The additional deaths likely reflect a mix of factors, including increased exposure of people with heart and lung disease to poor air quality from smoke and toxins released by the fires, as well as healthcare delays and disruptions, the study said. The findings "underscore the need to complement direct fatalities estimates with alternative methods to quantify the additional mortality burden of wildfires and of climate-related emergencies more broadly," the researchers wrote. Two wind-driven wildfires that erupted during the first week of January on opposite sides of Los Angeles damaged or destroyed nearly 16,000 structures combined - laying waste to much of the seaside district of Pacific Palisades and the foothill community of Altadena. Together, the blazes scorched 59 square miles (152 sq km), an area larger than Paris. The official tally of people who perished as a direct result of the fires stands at 31, after the most recent set of human remains were unearthed in Altadena in July, six months after the fires. Governor Gavin Newsom in February requested nearly $40 billion in wildfire aid from Congress. Some estimates put economic losses from the fires at more than $250 billion, making the conflagration one of the most costly natural disasters in U.S. history. The JAMA study acknowledged some limitations, saying the data may need to be revised upward in the future and the research did not reflect any fire-attributable deaths beyond Feb. 1.
